Economic evaluation of prevention of chemotherapy-induced nausea and vomiting (CINV): Palonosetron versus first generation 5-HT3 receptor antagonists;Valutazione dei costi della profilassi di un episodio di nausea e vomito indotto da chemioterapia: Palonosetron versus 5-HT3 inibitori di prima generazione

PharmacoEconomics - Italian Research Articles

Volumn 9, Issue 1, 2007, Pages 21-30

  Ravasio, Roberto ^a   Lucioni, C ^a  

^a Adis International Ltd   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOLASETRON MESILATE; GRANISETRON; ONDANSETRON; PALONOSETRON; SEROTONIN 3 ANTAGONIST; TROPISETRON;

ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA; DRUG COST; DRUG EFFICACY; DRUG INDUCED DISEASE; ECONOMIC EVALUATION; HEALTH CARE COST; HUMAN; PARAMETER; SENSITIVITY ANALYSIS; SYMPTOM;

EID: 34548840258     PISSN: 15909158     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03320567     Document Type: Article

References (25)

1. Bender CM, McDaniel RW, Murphy-Ende K, et al. Chemotherapy-induced nausea and vomiting. Clin J Oncol Nurs 2002; 6 (2): 94-102
2. Gralla R. Antiemetic Therapy. In: Bast R, Kufe D, Pollock R, et al., editors. Cancer Medicine (online version). Hamilton, Ontario: BC Decker, 2000
3. Koeller JM, Aapro MS, Gralla RJ, et al. Antiemetic guidelines: creating a more practical treatment approach. Support Care Cancer 2002; 10 (7): 519 22
4. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health Syst Pharm 1999; 56 (8): 729 64
5. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 1999; 17 (9): 2971 94
6. Ettinger DS, Bierman PJ, Bradbury B, et al. The NCCN antiemesis clinical practice guidelines in oncology (Version 1.2002) [monograph online]. Available from URL: http://www.nccn.org/physiciangls/index.htmI [accessed April 16, 2003].
7. Johnston D, Latreille J, Laberge F, et al. Preventing nausea and vomiting during days 2 7 following high dose cisplatin chemotherapy (HDCP). A study by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) [abstract]. Proc Am Soc Clin Oncol 1995; 14: 529
8. Grunberg SM. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 2004; 100 (10): 2261-8
9. 3 receptor antagonist, in vivo. Br J Pharmacol 1995; 114 (4): 860-6
10. Hesketh PJ. New treatment options for chemotherapy-induced nausea and vomiting. Support Care Cancer 2004: 12 (8); 550-4
11. Eisenberg P, MacKintosh FR, Ritch P, et al. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic, cisplatin based chemotherapy: a dose ranging, clinical study. Ann Oncol 2004; 15 (2): 330-7
12. 3 receptor anatagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003; 98 (11): 2473-82
13. Gralla R, Lichinitser M, Van der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14 (10): 1570-7
14. Aapro M, Bertoli L, Lordick F, et al. Palonosetron is effective in preventing acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Support Care Cancer 2003; 11: 391. Abstract A-17
15. Gruppo di lavoro ETEO. Epidemiologia dei trattamenti dell'emesi in oncologia. Giornale Italiano di Farmacia Clinica 2005; 19 (4).
16. Ihbe-Heffinger A, Ehlken B, Bernard R, et al. The impact of delayed CINV on patients, health resource utilisation and costs in German cancer centres. Anna Oncol 2004; 15 (3): 526-36
17. Jones AL, Hill AS, Soukop M, et al. Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 1991; 338 (8765): 483-7
18. Lofters WS, Pater JL, Zee B, et al. Phase III double-blind comparison of dolasetron mesylate and ondansetron and evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. J Clin Oncol 1997; 15 (8): 2966-73
19. Park JO, Rha SY, Yoo NC, et al. A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy. Am J Clin Oncol 1997: 20 (6): 569-72
20. Adams M, Soukop M, Barley V, et al. Tropisetron alone or in combination with dexamethasone for the prevention and treatment of emesis induced by non-cisplatin chemotherapy: a randomized trial. Anticancer Drugs 1995; 6 (4): 514-21
21. Liau CT, Chu NM, Liu HE, et al. Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes. Support Care Cancer 2005; 13 (5): 277-86
22. Ballatori E, Roila F, Ruggeri B, et al. Costs of delayed emesis in Italy. Presentato al 29° Congresso della Società Europea di Oncologia Medica (ESMO). Vienna, 29 ottobre-2 novembre 2004. Abstract 555PD
23. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. (Edizione italiana a cura di Fattore G, Garattini L, Lucioni C) Metodi per la valutazione economica dei programmi sanitari. Roma: Il Pensiero Scientifico Editore, 2000
24. Weinstein MC, Fineberg HV L'analisi della decisione in medicina clinica. Milano: Fondazione Smith Kline-FrancoAngeli editore 1984
25. Tarricone R, Girolami F. Economie evaluation of a new antiemetic drug - Palonosetron versus Ondansetron. Assessment of the drug price ratio in five European countries. Clin Drug Invest 2005; 25 (9): 597-608